EUVIMEDOpdag EUVIMED
Vergleichsstudie

Risk of Hepatocellular Cancer in U.S. Patients With Compensated Cirrhosis Treated With Direct‐Acting Antivirals Versus Interferon

Hashem B El-Serag, Hao Duong, Michelle Luster, Fasiha Kanwal, Deanna D Hill, Margaret Burroughs, Candido Hernandez, Barbara A Haber, Lois M Larsen, John F Marcinak, Lani R Wegrzyn, Xian Yu and 2 more

Alimentary Pharmacology & Therapeutics · 2025

DOI: 10.1111/apt.18525 ↗

At a glance

Vergleichsstudie in Alimentary Pharmacology & Therapeutics, 2025. Written by Hashem B El-Serag and 13 co-authors. Institution: Department of Medicine, Baylor College of Medicine, Houston, Texas, USA. Major MEDLINE topics: Antiviral Agents, Carcinoma, Hepatocellular, Liver Neoplasms, Liver Cirrhosis. Cited 7 times so far (Crossref); 45 references. Funded by: NIDDK NIH HHS, DAA PASS Hep C Consortium, Veterans Administration Center for Innovations in Quality, Effectiveness and Safety, Michael E. DeBakey VA Medical Center.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Few studies have examined the risk of de novo hepatocellular carcinoma (HCC) among hepatitis C virus (HCV)–infected patients with cirrhosis who received interferon (IFN)‐free direct‐acting antiviral (DAA) therapy relative to patients who received IFN‐containing therapy or remained untreated.

Aims

To estimate the risk of de novo HCC with DAA treatment in cirrhotic HCV patients compared to no anti‐HCV treatment and those treated with IFN‐based therapy.

Methods

We identified patients with chronic HCV infection and compensated cirrhosis in the US Department of Veterans Affairs healthcare system treated with IFN (2005 to 2013) or DAAs (2013 to 2017). We compared the risk of de novo HCC for patients treated with DAAs, IFN‐containing regimens or no treatment after accounting for differences in demographics, alcohol and drug abuse, comorbidities, laboratory values, healthcare utilisation, prior HCV treatment and HCC surveillance.

Results

A total of 53,847 patients contributed to untreated time, 27,147 patients contributed to DAA‐treated time (15,641 contributed to both untreated and DAA‐treated times) and 6809 patients contributed to IFN‐treated time. HCC risk associated with DAA treatment was significantly lower than untreated [adjusted HR: 0.70 (95% CI: 0.65–0.74)]. The risk of HCC was not significantly different for patients treated with DAA compared with those treated with IFN [adjusted HR: 0.98 (95% CI: 0.87–1.10)].

Conclusions

The study shows a reduced risk of de novo HCC among patients with chronic HCV–related compensated cirrhosis who received DAA treatment compared to that of untreated patients. There were no differences in HCC risk between DAA‐treated and IFN‐treated patients.

Subjects

MeSH terms (MEDLINE)

Antiviral AgentsCarcinoma, HepatocellularLiver NeoplasmsLiver CirrhosisHepatitis C, ChronicInterferonsHumansMaleFemaleMiddle AgedUnited StatesAgedRisk Factors

Author keywords

cohort studycollider biasepidemiologyliver cancerviral hepatitis

Substances

Antiviral AgentsInterferons

Authors and institutions

  • Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
  • Center for Innovations in Quality, Effectiveness and Safety, Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas, USA.
  • Merck & Co., Inc., Rahway, New Jersey, USA.
  • AbbVie Inc., North Chicago, Illinois, USA.
  • Gilead Sciences, Inc., Foster City, California, USA.

ORCID profiles: Jennifer R Kramer

Funding

  • NIDDK NIH HHS
  • DAA PASS Hep C Consortium
  • Veterans Administration Center for Innovations in Quality, Effectiveness and Safety, Michael E. DeBakey VA Medical Center
  • Cancer Prevention and Research Institute of Texas
  • National Institute of Diabetes and Digestive and Kidney Diseases

Cite

APA

El-Serag, H. B., Duong, H., Luster, M., Kanwal, F., Hill, D. D., Burroughs, M., Hernandez, C., Haber, B. A., Larsen, L. M., Marcinak, J. F., Wegrzyn, L. R., Yu, X., Richardson, P., & Kramer, J. R. (2025). Risk of Hepatocellular Cancer in U.S. Patients With Compensated Cirrhosis Treated With Direct‐Acting Antivirals Versus Interferon. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.18525

Vancouver

El-Serag HB, Duong H, Luster M, Kanwal F, Hill DD, Burroughs M, et al. Risk of Hepatocellular Cancer in U.S. Patients With Compensated Cirrhosis Treated With Direct‐Acting Antivirals Versus Interferon. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.18525

BibTeX
@article{ElSerag2025,
  author = {El-Serag, Hashem B and Duong, Hao and Luster, Michelle and Kanwal, Fasiha and Hill, Deanna D and Burroughs, Margaret and Hernandez, Candido and Haber, Barbara A and Larsen, Lois M and Marcinak, John F and Wegrzyn, Lani R and Yu, Xian and Richardson, Peter and Kramer, Jennifer R},
  title = {Risk of Hepatocellular Cancer in U.S. Patients With Compensated Cirrhosis Treated With Direct‐Acting Antivirals Versus Interferon},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2025},
  doi = {10.1111/apt.18525}
}
Start for free →